Scleroderma

Off-Label Coverage of Mycophenolate for Scleroderma under Medicare Part D

January 6, 2020 • By From the College

FDA Approves Nintedanib for SSc-ILD, But Temper Your Expectations

December 18, 2019 • By Michael Putman, MD

Case Report: A Patient Develops Scleroderma Renal Crisis

October 18, 2019 • By Adria Madera-Acosta, MD, Teresa Sosenko, MD, & Diana Girnita, MD, PhD

Can REVEAL Tool Predict Survival in SSc-Related Pulmonary Arterial Hypertension?

September 17, 2019 • By Mary Beth Nierengarten

Light micrograph of a vascular lesion (center) caused by systemic sclerosis.

Case Report: Can Salt-&-Pepper Skin Mean Systemic Sclerosis?

September 17, 2019 • By Wesam Gouda, MBBCh, MSc; Abdelhafeez Moshrif, MBBCh, MSc, MD; Fatma H. El Nouby, MBBCh, MSc, MD; & Amal Fehr, MBBCh, MSc, MD

Study Probes New Gene Therapy for Severe, Localized Scleroderma (Morphea)

August 16, 2019 • By Ruth Jessen Hickman, MD

New Studies Identify Possible Markers of Early Systemic Sclerosis

August 16, 2019 • By Bryn Nelson, PhD

Lessons Learned from Two Scleroderma Lung Studies (Plus a Third That’s Recruiting Sites)

August 16, 2019 • By Elizabeth R. Volkmann, MD, MS, Michael D. Roth, MD, Donald P. Tashkin, MD, Cathie Spino, ScD, & Dinesh Khanna, MD, MS

Recent Trials Investigated Targeted Therapies for Systemic Sclerosis

May 18, 2019 • By Mary Beth Nierengarten

Markers for Severe Gastrointestinal Dysmotility in Systemic Sclerosis

May 18, 2019 • By Larry Beresford